

Curriculum Vitae

Part I: General Information

Date Updated: June 26, 2017

Name: Satish N. Nadig, MD, DPhil (Oxon), FACS

Professional Address: 96 Jonathan Lucas Street
MSC 613/CSB 409
Charleston, SC 29425

Email: nadign@musc.edu

Date of Birth: March 9, 1978

Place of Birth: Columbia, SC USA

Education:

Washington University 8/95-5/99
St. Louis, MO
Bachelor of Arts, Biology and Anthropology (A.B.)
cum laude

Medical University of South Carolina 8/99-5/03
Charleston, SC
Doctor of Medicine (M.D.)

University of Oxford 8/05- 6/08
Balliol College (D.Phil.) (Date of Defense 10/08)
Oxford, United Kingdom
Doctor of Philosophy- Transplant Immunology
"Immunoregulation of Transplant Arteriosclerosis"
Supervisor: Professor Kathryn J. Wood
Examiners: Professor Joren Madsen
Dr. Robyn Choudhary

Postdoctoral Training:

Beth Israel Deaconess Medical Center 7/03- 6/04
Harvard University Medical School
Boston, MA
Internship in General Surgery

Beth Israel Deaconess Medical Center 6/04- 6/11
Harvard University Medical School
Boston, MA
Residency in General Surgery
Administrative Chief Resident 2010-2011

University of Michigan Health Systems 2011-2013
Ann Arbor, MI
Fellow- Section of Transplantation Surgery

Certification:

Certified, American Board of Surgery 2012
Certified, Fundamentals of Laparoscopic Surgery 2009
Certified, ASTS Approved Fellowship in Multiorgan Transplantation
(Liver, Kidney, Pancreas, Pediatric Transplant) 2013

Licensure:

Permanent Full License – Michigan 2011-2013
Permanent Full License- South Carolina 2013-Present

Academic Appointments:

University of Michigan Health Systems 2011-2013
Ann Arbor, MI
Clinical Lecturer
Department of Surgery
Section of Transplantation Surgery

Medical University of South Carolina 2013- 2017
Charleston, SC
Assistant Professor
Department of Surgery- Division of Transplant Surgery
Department of Microbiology and Immunology

Medical University of South Carolina 2013-2017
Charleston, SC
Assistant Professor
Department of Microbiology and Immunology

Medical University of South Carolina 2017
Charleston, SC
Assistant Professor
Department of Pediatrics-Critical Care

Medical University of South Carolina 2017- Present
Charleston, SC
Associate Professor
Department of Surgery, Pediatrics- Critical Care, &
Microbiology/Immunology

Experience

ToleRaM Nanotech, LLC 2014-Present
Charleston, SC
Co-Founder and Chief Medical Officer (CMO)
Bioprocess International “Emerging Company” Award 2014
TechConnect National Innovation Awardee 2016

Hospital or Affiliated Institution Appointments:

Associate Resident Director for Quality Assurance	2009-2010
Attending Surgeon, University of Michigan Health Systems Ann Arbor , MI	2011-2013
Attending Surgeon, Medical University of South Carolina Charleston, SC	2013-Present
Graduate Faculty, Microbiology and Immunology, MUSC Charleston, SC	2013-Present
Faculty Advisory Board, Foundation for Research and Development, MUSC Charleston, SC	2013-Present
Director, South Carolina Investigators in Transplantation	2013-Present
MUSC-Surgical Entrepreneurship Committee	2014-Present
Co-Director Lee-Patterson Allen Transplant Immunobiology Laboratory	2014-Present
Associate Vice Chairman of Research, Dept of Surgery	2016-Present
Director, Center for Cellular Therapy	2017-Present
Director, Pediatric Kidney and Liver Transplantation	2017-Present

Professional Societies and Service:

Massachusetts Medical Society, Member	2003-2011
American Society of Transplantation (AST), Member	2005-Present
British Transplantation Society (BTS), Member	2005-2008
The Transplantation Society (TTS), Member	2005-Present
International Society for Heart and Lung Transplantation (ISHLT) Moderator 2008 Annual Meeting Session: "Regulatory T Cells in Thoracic Transplantation" Boston, MA	2005-Present
American Hepato-Pancreato-Biliary Association (AHPBA)	2008-Present
AHPBA, Research Committee	2013-Present
AHPBA, Program Committee	2011-2013
Moderator: Oral Poster II "Tricks of the Trade" Miami, FL	
Moderator: Oral Presentation "Transplant/Biliary Category" Miami, FL	
American Society of Transplant Surgeons (ASTS)	2011-Present
ASTS, Communications Committee	2013-Present
Liaison to the Workplace for Life Campaign (2014) Co-Chairman (2016-2019)	
Association for Academic Surgery	2013-Present
International Pediatric Transplant Association	2017-Present

Honors & Awards:

Sigma Xi Scientific Research Honor Society	1999
Nominated for AOA (Medical Student National Honor Society) as a junior student	2001
William H. Lee, Jr. Memorial Award in Cardiothoracic Surgery	2002
Appointed to peer-selected Graduate Medical Education Advisory Committee (Junior Resident)	2005
Recipient of the University of Oxford-Clarendon Scholarship	2005
Recipient of the American Society of Transplantation- International Fellowship Award	2005
Delegate to 45 th Annual Academy of Achievement International Achievement Summit – Los Angeles, CA	2006
Recipient of the National Institute of Health Loan Repayment Program Award	2006

Recipient of the International Society for Heart and Lung Transplantation Research Fellowship Award	2007
The Transplantation Society's new Key Opinion Leader Award (nKOL)- Sydney, Australia	2007
Oxford Medical School- Teacher of the Month, December	2007
Philip K. Caves Young Investigator Award Recipient ISHLT Annual Meeting- Boston, MA	2008
Appointed to peer-selected Graduate Medical Education Advisory Committee (Senior Resident)	2009
BIDMC Surgical Service Resident Teacher Award	2011
ASTS Junior Faculty- Young Investigator Award	2014
MUSC Teacher of the Block	2014
AST-CEOT Faculty Young Innovator Award	2014
AOA Alumni Award	2014
"Emerging Company" Award, Bioprocess International	2014
Fellow of the American College of Surgeons (FACS)	2014
ASTS Junior Faculty- Young Investigator Award	2015
Forty under 40; Charleston, SC	2015
ASTS Vanguard Prize	2016
Mentor- ASTS Presidential Student Mentor Award	2016
TechConnect National Innovation Awardee	2016
Nominated-Governor's Young Scientist Award for Excellence in Scientific Research	2016
Rising Star Award- American Society of Transplant Surgeons	2017
Performed SC's first pediatric domino liver transplant	2017

Activities:

Washington University Men's Soccer Team	1995-1997
Balliol College MCR Football (Soccer) Team- Captain (2006-07)	2005-2008
Theatre 99 Improv Comedy	2015-Present

Languages: English & Kannada (Indian Dialect)

Part II: Research, Teaching, and Clinical Contributions

A. Narrative

Research Fellow Department of Cardiology

Washington University Medical School -- St. Louis, MO **5/97-12/97**

Research under Dr. Daniel Ory devoted to creating a self-contained retrovirus for inducible expression of cDNA's within target cells. During the summer months I worked as a full time assistant. Approximately 10 hours per week were spent between the months of August to December

Research Fellow – Division of Transplant Surgery

Medical University of South Carolina -- Charleston, SC **6/00-5/03**

Research fellow under Kenneth Chavin M.D., Ph.D. I studied the effects of ischemia-reperfusion on steatotic livers during transplantation. I was a full-time fellow during the months of June- August and I continued to work as a part-time fellow during the remainder of medical school.

Graduate Research Fellow- Nuffield Department of Surgery 7/05-6/08

University of Oxford- Oxford, UK

Doctor of Philosophy obtained in Transplant Immunology under the supervision of Kathryn J. Wood, D.Phil. Using the murine aortic transplant model, I investigated the role of regulatory T cells in the induction and maintenance of immunologic tolerance in transplanted allografts and their impact on transplant arteriosclerosis.

Clinical Tutor in Surgery – Nuffield Department of Surgery 8/07- 5/08

University of Oxford – Oxford, UK

Clinical lecturer for final year medical students at the University of Oxford Medical School. Responsibilities included both bedside teaching and basic science tutorials on a variety of surgically-related topics.

Current Basic Research

2013-Present

The focus of my research is centered around immunoregulation and targeted drug delivery in the setting of solid organ transplantation. Specifically, I am interested in the utilization of triggered- release nanoparticle therapy as a vehicle for immunotherapeutics. In addition, our laboratory focuses on cellular therapies including the use of particular subsets of CD4+ T cells expressing the markers CD25hi CD127lo FOXP3+ which have been termed “regulatory T cells (Treg)” for their natural and inducible suppressive capacity. Harnessing the suppressive capacity of Treg and applying them to the clinic is under vigorous investigation at present, and is now in early stages of clinical trials. Central to our investigations is the use of animal models to test the uptake, efficacy, and regulatory properties of self-assembling micelle nanoparticles carrying rapamycin, which has been shown to bolster populations of Treg thereby conferring a tolerogenic phenotype.

Current Clinical Research

Clinical research contributions have focused on areas primarily involving liver, kidney, and pancreas transplantation along with vascular access and general surgery in organ failure patients. These contributions include investigating the utilization of marginal donor organs in transplantation, identification of undercharacterized pancreatic tumors, optimizing immunosuppression in liver transplant recipients through clinical trials, and reporting various cases and series of unique patient care issues.

Teaching

Ongoing mentorship of students, resident, and fellows.	
Sophomore Advisor for Freshman Medical Students	2000-2001
Pathology Tutor for Sophomore Medical Students	2000-2001
BIDMC Housestaff Education Committee	2009-2011
Advisor to John Warren Surgical Society Harvard Medical School	2010-2011
Course Lecturer- MBIM-735. Mol & Cell Basis of Inflamm & Immunity MUSC Graduate School	2014-present
MUSC Teacher of the Block Award	2014
Nominated- MUSC Golden Apple Award	2015
Faculty- NIH T32 postdoctoral immunology training program	2016

PhD Thesis Committee Member

Jacob Bower	2014-2017
Ahmad Mashmouhi	2014-2016
Sanket Pattanaik	2017-Present

Students Mentored

Trainee Last Name	Trainee First Name	Training Period	Training Type	Prior Education	Title of Project	Current Position
Cheng	Qi	2015-2017	Post-Doctoral Fellow	MD, Tongji Medical College	Complement Inhibition in Lung Transplantation	Assistant Professor, Tongji Medical College Huazhong University
Sandifer	Benjamin	2016	AST-TIRN	BA, Clemson University Biological Sciences 2012	Assessing therapeutic potential of ACT1 to reduce cardiac endothelial cell activation	AST/Transplant&Immunology Research Network-Summer Internship
Dong	Catherine	2016	NIH-Summer Health Program	BS, USC Biochemistry 2015	The impact of cellular immunometabolism in transplantation	NIH- Summer Health Professionals Program ASTS-Presidential Student Mentor Grant
Tran	Danh	2015-Present	MD/PHD (MSTP) Student	BS, UCLA, Microbiology, Immunology, and Molecular Genetics, 2011	Implications of Cellular Immunometabolism in Solid-organ Transplantation	Current Trainee NIH T32 Pre-doctoral Scientist Recipient
Patel	Kunal	2015-Present	Surgical Resident	MD, University of Virginia, 2013	Targeted Ex Vivo Nanotherapy for Use in Cardiac Transplantation	Current Trainee NIH T32 Recipient
Alhudaithi	Sulaiman	2014-2016	Master's Student	BS, King Saud University, Pharmaceutical Sciences, 2011	The Role of Targeted Rapamycin in Transplantation	Pharmacologist
Finnegen	Ryan	2015-2017	Master's Student	BS, Davis and Elkins College, Biology 2014	Gap and tight Junction Stabilization in Cardiac Translation	Laboratory Technician TIBL
Bazzle	Grace	2015-Present	Master's Student	BS, Charleston Southern University, Biochemistry, 2013	Rapamycin Encapsulated Nanoparticles as a Pre-treatment in lung transplantation	Current Trainee
Qi	Cheng	2015-Present	Post-doctoral Scientist	MD, Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.	Modulation of complement activation pathways to optimize transplant tolerance induction	Post-Doctoral Scientist, MUSC
Dennis	William	2014	NIH-Summer Health Program	BA, Duke University, Chemistry and Mathematics, 2012	Nanoparticle Therapy for Targeted Drug Delivery in Organ Transplantation	Surgical Resident- Orlando
Zhu	Peng	2013-2015	Post-doctoral Scientist	Attending, Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.	Gap and Tight Junction modulation in transplantation	Assistant Professor, HPB and Transplant Surgery, Tongji Hospital, Wuhan, Hubei, China

B. Funding

Ongoing Research Support

Patterson –Barclay Foundation (PI-Nadig) 04/24/2016 Funded \$471,000

Merging Bioengineering and Immunology

Unrestricted family foundation donation of \$471,000 to the Transplant Immunobiology Laboratory to investigate novel methods of improving transplantation via bioengineering and immunology.

Medical University of South Carolina, Department of Surgery (PI-Nadig) 07/11/2013 - 07/30/2016

Funded \$300,000

The Induction of Transplant Tolerance using Nanoparticle-Based Targeted Drug Delivery

The goal of this project is to utilize novel nanoparticle therapy as a targeted package for immunotherapeutics in order to prevent acute and chronic rejection of organ allografts while obviating systemic side-effects.

Medical University of South Carolina, SCTR K12 (PI-Nadig) 07/01/2014 – 06/30/2016

Funded \$185,200; Effort 40%

Nanoparticle Therapy for Targeted Drug Delivery in Organ Transplantation

The goal of this project is to investigate the use of nanoparticles as an alternative delivery device for immunotherapeutics in the setting of solid organ transplantation.

National Institute of Health (NIH), K08 EB019495-01A1 (PI-Nadig) 04/01/2016 – 03/31/2019

Funded \$581,046; Effort 75%

Nanoparticle Therapy for Targeted Drug Delivery in Organ Transplantation

The goal of this project is to investigate the use of targeted rapamycin micelles conjugated to complement receptor 2 as a targeting moiety directly to transplanted organs in vivo as a means for local immunosuppression.

National Institute of Health (NIH)/ NIBIB R03 (PI- Broome; Co-I Nadig): 09/01/2016-

09/01/2018 Funded \$50,000; Effort 10%

Nanotherapeutic Delivery of Resveratrol Analogs as a Pre-Treatment of Allografts in Solid Organ Transplantation

This project aims to investigate targeted resveratrol delivery ex vivo using nanoparticles in transplantation.

National Institute of Health (NIH)/ NHLBI 1R43 HL131360-01A1-SBIR (FirstString PI Ghanekar/ MUSC PI-Atkinson/CoI- Nadig) Funded: \$89,000; Effort 2.5%

Stabilization of gap/tight junctions to ameliorate brain death induced endothelial cell injury.

National Institute of Health (NIH)/ NIAID 1U01AI132894-01 (PI-Tomlinson/Atkinson/CoI-Nadig) Funded: \$1,250,000 Effort 3%

Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy

NIH/NIDCR RO1 (PI- Yost; Co-I Nadig): Renewal Submitted

An Enabling Technology for Improving Engraftment of Implanted Materials and Cells

Project dedicated to developing an enabling technology to improve the engraftment of cellularized implants by modulating the early inflammatory process and promoting nascent microvascular beds.

C. Report of Current Research

Activities Editorial Service:

Ad Hoc Reviewer-

Transplantation

HPB

HPB International

American Journal of Transplantation

Liver Transplantation

Clinical Transplantation

Pediatric Transplantation

PLoS 1

Nanomedicine

Invited Lectures: Local, National, and International Contributions

1. **New Key Opinion Leader Lecture.** The Transplantation Society. Sydney, Australia. *The impact of human regulatory T cells on transplant Arteriosclerosis.* 2007. *International*
2. **Grand Rounds.** Beth Israel Deaconess Medical Center Dept. of Surgery. Harvard Medical School. Boston, MA. *The Impact of Regulatory T cells on Transplant Arteriosclerosis.* September 2008. *Local*
3. **Grand Rounds.** Mount Auburn Hospital Dept. of Surgery. Harvard Medical School. Boston, MA. *The Immunoregulation of Chronic Transplant Rejection: from Bench to Bedside.* June 2010. *Local*
4. **Vascular Biology and Therapeutics Seminar.** Yale University Division of Immunology. New Haven, CT. *The Immunoregulation of Transplant Arteriosclerosis.* June 2010. *National*
5. **Grand Rounds.** Medical University of South Carolina. Dept. of Surgery. Charleston, SC. *The Immunoregulation of Transplant Arteriosclerosis: from bench to bedside.* Aug 2010. *National*
6. **Grand Rounds.** St. Vincent's Hospital Dept. of Surgery. Worcester, MA. *The Immunoregulation of Chronic Rejections: Clinical Implications and Therapies.* Sept 2010. *Local.*
7. **TRIG 30years.** University of Oxford. *Targeted Drug Delivery: crossing the bridge.* June 2013. *International*
8. **MUSC- Microbiology & Immunology Seminar.** Targeted Drug Delivery in Solid Organ Transplantation: *an emerging concept.* Nov 2013. *Local.*
9. **MUSC – Preclinical Imaging Meeting.** Targeted Drug Delivery in Solid Organ Transplantation: *an emerging concept.* Dec 2013. *Local.*
10. **MUSC – Surgical Grand Rounds.** Nanoparticle Therapy in Transplantation: *What is Possible?* Dec 2013. *Local.*
11. **ASTS Winter Meeting.** Towards targeted Drug Delivery in Transplantation: use of immunosuppressant nanoparticle therapy. January 2014. *National.*
12. **Transplant Grand Rounds.** Transplant Immunology. MUSC. November 2014. *Local*
13. **ASTS Winter Meeting.** The Basic Science Grand Slam. January 2015. *National*
14. **ASTS Winter Meeting.** Targeted Nanotherapy Dampens Endothelial Cell Antigen Presentation and Inflammation. January 2015. *National.*
15. **Grand Rounds.** Targeted Nanotherapy in Organ Transplantation: *from bench to bedside.* University of North Texas. Fort Worth, TX. January 2015. *National*
16. **Sri Ahuja Surana- India International Knowledge Forum.** *The Year in Transplantation: a new era of merging bioengineering with transplant surgery.* Bangalore, India 2015. *International.*
17. **Emerging Issue in Organ Transplantation.** *Targeted Drug Delivery in*

- Transplantation: an emerging concept.* Charleston, SC. 2015. *National.*
18. **1st Annual Nephrology Transplant Symposium** *The future of kidney transplantation.* Charleston, SC. 2015. *Local.*
 19. **ASTS Vanguard Prize Recipient** *Immunosuppressive Nano-Therapeutic Micelles Downregulate Endothelial Cell Inflammation and Immunogenicity.* Miami, FL 2016. *National*
 20. **Grand Rounds.** 62 years of Renal Transplantation: The Journey Continues...Medical University of South Carolina. Department of Urology. Charleston, SC. April 2016. *Local.*
 21. **Pulmonary & Critical Care Grand Rounds.** Smart Drugs: the next era of transplantation. Medical University of South Carolina. Department of Medicine. Charleston, SC. July 2016. *Local.*
 22. **University of Tennessee- Chattanooga Visiting Professor.** Smart Drugs: the next era of transplantation. UTC Department of Surgery. Chattanooga, TN. Sept 2016. *National*
 23. **2nd Annual Transplant Nephrology Symposium.** Smart Drugs: the next era of transplantation. Charleston, SC. Oct 2016. *Local*
 24. **The Mayo Clinic Visiting Professor.** Smart Drugs: the next era of transplantation. Department of Surgery. Scottsdale, AZ. Oct 2016. *National*
 25. **The University of Wuhan Visiting Professor.** Liver Transplantation in South Carolina. International Hepatopancreatic Biliary Association. Wuhan, China. Dec 2016. *International*
 26. **Grand Rounds.** *The Jetsons:* The next era of Organ Transplantation. Medical University of South Carolina. Department of Surgery. Charleston, SC. July 2017. *Local.*

Part III. Bibliography:

Patents

(2014) Targeted Nanocarriers for the Administration of Immunosuppressive Agents. P1446; 10075-034PV, filed Jan 2014. Provisional Patent.

(2014) cRGD-targeted Rapamycin Micelle (cRaM) as a Therapeutic in Transplantation. P1446; 10075-034PV, filed Jan 2014. Provisional Patent.

(2015) Nanocarriers for Delivery of Alpha-1-Antitrypsin (A1AT). P1536; 10075-039PV, filed Feb 2015. Provisional Patent.

(2015) Donor Organ Preservation Solution, P1577; Filed May 2015. Provisional Patent

Publications (* authors contributed equally to the manuscript)

1. **Satish N. Nadig**, Andrew R. Deibler, Troy J. Marlow, M. Kathleen Wiley, Stephen I. Schabel. Retained needle fragments in patients with diabetic neuropathy. *JAMA* 2000 Jun 1;283(23):3072
2. Andrew R. Deibler, **Satish N. Nadig**, Charles M. Heaton, Troy J. Marlow, Young S. Song, David M. Shackelford, Juan Olazagasti, Nancy S. Curry, Sally E. Self, Stephen I. Schabel. The "Rolling Stones." *Emergency Radiology.* 2001 8(1): 29-34
3. **Satish N. Nadig**, Andrew R. Deibler, Tarek M. El Salamony, Gerald W. Hull, Nabil K. Bissada. Small Cell Carcinoma of the Prostate: An Underrecognized Entity. *Canadian Journal of Urology.* 2001;8(1):1207-1210
4. Andrew R. Deibler, **Satish N. Nadig**, Nancy S. Curry, Nabil K. Bissada, Gerald W. Hull.

Intrarenal Varices Presenting as an Enhancing Renal Mass with Calcifications. *Journal of Urology*. 2001 Sept.; 166:997-998

5. **Satish N. Nadig** and Mark I. Block. "Drowned-Lung" Following Lobectomy and Radiation Therapy: A Case Report. *Journal of SCMA*. 2003 Feb.; 99(2): 26-29
6. **Satish N. Nadig MD**, Basker Periyasamy MD, Stephen F. Shafizadeh DC, Carmen Polito BS, Ryan Fiorini BS, David Rodwell BS, Zachary Evans BS, Gang Cheng MD PhD, Dana Dunkelberger PhD, Michael Schmidt PhD, Sally E. Self MD, Kenneth D. Chavin MD, PhD. Hepatocellular ultrastructure after ischemia/reperfusion injury in human orthotopic liver transplantation. *Journal of Gastrointestinal Surgery*. 2004; 8(6): 695- 700
7. **Satish N. Nadig MD**, Charles F. Bratton MD, and Seth Karp MD. Marginal Donors in Liver Transplantation: Expanding the Donor Pool. *Current Surgery*. 2007;64(1):46-50
8. Gregor Warnecke, Andrew Bushell, **Satish N. Nadig**, and Kathryn J. Wood. Regulation of Transplant Arteriosclerosis by CD25⁺CD4⁺ T cells Generated to Alloantigen In Vivo. *Transplantation*. 2007; Jun 15.83(11):1459-1465.
9. Cherry I. Kingsley*, **Satish N. Nadig***, Kathryn J. Wood. Transplantation Tolerance: Lessons from Experimental Rodent Models. *Transplant International*. 2007 Oct;20(10):828-41
10. Gregor Warnecke*, Gang Feng*, R. Goto, **Satish N. Nadig**, Ross Francis, Andrew Bushell, and Kathryn J. Wood. CD4⁺ Regulatory T cells generated *in vitro* with IFN- γ and Allogeneic APC inhibit transplant arteriosclerosis. *Am. J. Path.* 2010 Jul;177(1):464-72.
11. **Satish N. Nadig***, Joanna Więckiewicz*, Douglas C. Wu, Gregor Warnecke, Wei Zhang, Shiqao Luo, David P. Taggart, and Kathryn J. Wood. *In vivo* Prevention of Transplant Arteriosclerosis by *ex vivo* Expanded Human Regulatory T Cells. *Nature Med.* 2010 Jul;16(7):809-13
12. Fadi Issa, Joanna Hester, Ryoichi Goto, **Satish N. Nadig**, Tim Goodacre, and Kathryn Wood. Ex-vivo expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. *Transplantation*. 2010 Dec 27;90(12):1321-7
13. Gang Feng, **Satish N. Nadig**, Liselotte Backdahl, Stefan Beck, Ross S. Francis, Alexandru Schiopu, Kathryn J. Wood, and Andrew Bushell. Ex vivo T cell reprogramming by inhibition of PDE₃ produces functional regulatory T cells that prevent transplant rejection. *Science-TM*. 2011; May 18 3(83).
14. **Satish N. Nadig**, Ivan Pedrosa, Jeffrey Goldsmith, Mark P. Callery, and Charles M. Vollmer. Clinical Implications of Non-neoplastic Mucinous Cysts of the Pancreas. *Pancreas*. 2011. October 19.
15. Alexandru Schiopu, **Satish N. Nadig**, Ovidiu S. Cotoi, Joanna Hester, Nico Van Rooijen, and Kathryn J. Wood. Inflammatory Ly-6Chi monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients. *Atherosclerosis*. 2012 Aug;223(2):291-8.
16. Joanna Hester, Alexandru Schiopu, **Satish N. Nadig**, and Kathryn J. Wood. Low dose rapamycin treatment increases the ability of human regulatory T cells to inhibit

transplant arteriosclerosis in vivo. American Journal of Transplantation. 2012; Aug; 12(8):2008-16.

17. **Satish N. Nadig***, Shawn J. Pelletier*, David D. Lee, John M. Ammori, Michael J. Englesbe, Randall S. Sung, John C. Magee, Robert J. Fontana, and Jeffrey D. Punch. A Prospective, Randomized Trial of Complete Steroid Avoidance in Liver Transplantation: follow-up of over 7 years. HPB. 2013 Apr;15(4):286-93.
18. **Satish N. Nadig**. Current Status of Risk Evaluation and Mitigation Strategies in Organ Transplantation. Immunology Report. 9(1) 2012: 18-22.
19. Douglas Wu, Joanna Hester, **Satish Nadig**, Wei Zhang, Piotr Trzonkowski, Derek Gray, Paul Johnson and Kathryn J. Wood. Ex vivo expanded human CD25^{high}CD4⁺ regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. Transplantation. 2013 Aug.
20. Jessica L. Mellinger, Lorenzo Rossaro, Willscott E. Naugler, **Satish N. Nadig**, Henry Appelman, William M. Lee, and Robert J. Fontana. Epstein-Barr Virus (EBV) Related Acute Liver Failure: A Case Series from the US Acute Liver Failure Study Group. Dig Dis Sci. Jan 2014.
21. **Satish N. Nadig** and Julie A. Wright Nunes. Preoperative Medication Management: Filling in the gaps. South Med J. 2013 Aug;106(8):447-8.
22. Arun P. Palanisamy, Clarence E. Schiltz, Nicole A. Pilch, Kelly J. Hunt, **Satish N. Nadig**, Jacob E. Dowden, John W. McGillicuddy, Prabhakar K. Baliga, Kenneth D. Chavin, David J. Taber. Cardiovascular Risk Factors Contribute to Disparities in Graft Outcomes in African American Renal Transplant Recipients: A Retrospective Analysis. *Blood Pressure*. 2014 Jul 22:1-9.
23. Arun P. Palanisamy PhD*, David J. Taber PharmD*, Alton G. Sutter PhD, **Satish N. Nadig MD, PhD**, John W. McGillicuddy MD, Prabhakar K. Baliga MD, Kenneth D. Chavin MD Clinical Outcomes and Costs Associated with In-Hospital Biliary Complications after Liver Transplantation. *J Gastrointest Surg*. 2014. Oct 16
24. Mathur AK, **Nadig SN**, Kingman S, Lee D, Sonnenday CJ, Welling TH. The effect of intra-operative stenting on biliary complications following orthotopic liver transplantation. Clin Transplant. 2015 Jan 21.
25. Palanisamy AP, Al Manasra AR, Pilch NA, Dowden JE, **Nadig SN**, McGillicuddy JW, Baliga PK, Chavin KD, Taber DJ. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. Clin Transplant. 2014 Dec 31.
26. **Satish N. Nadig**, Suraj K. Dixit, Natalie Levey, Scott Eskilsen, Kayla Miller, William Dennis, Carl Atkinson, and Ann-Marie Broome. Immunosuppressive nanotherapeutic micelles downregulate endothelial cell inflammation and immunogenicity. RSC Advances 5, 43552-43562, 2015.
27. Peng Zhu, Scott Eskilsen, Carl Atkinson, Xiao-ping Chen, **Satish N. Nadig**. A simplified cuff technique for abdominal aortic transplantation in mice. Journal of Surg Res. S0022-4804(15)00876-8. 2015 Aug 28. [Epub ahead of print]
28. Kunal Patel, Carl Atkinson, Ann-Marie Broome, John McGillicuddy, Kenneth Chavin,

Satish N. Nadig. Utilization of Machine Perfusion and Nanotechnology in Liver Transplantation. *Current Transplantation Reports*. (2015) 2:303–311.

29. Cameron L. Jordan, David J. Taber, Maggee O. Kyle, James Connelly, Nicole W. Pilch, James Fleming, Holly B. Meadows, Charles F. Bratton, **Satish N. Nadig**, John W. McGillicuddy, Kenneth D. Chavin, Prabhakar K. Baliga, Ibrahim F. Shatat and Katherine Twombly. Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. *Pediatric Transplantation*. Epub ahead of print 8 NOV 2015.
30. **Nadig SN.** Transplant Arteriosclerosis. *Transplantation*. 2016 Nov;100(11):2249-2250.
31. Kunal Patel, Carl Atkinson, Danh Tran, **Satish N. Nadig.** Nanotechnological Approaches to Immunosuppression and Tolerance Induction. *Current Transplantation Reports*. Accepted
32. Palanisamy AP, **Nadig SN**, Chedister, G, Dowden, J, Koch D, Stoll W, McGillicuddy J, Chavin KD. Use of Intra-Aortic Counterpulsation in Cardiogenic Shock Post Liver Transplantation. *Clin Transplant*. 2017, May 10. Epub ahead of print.
33. Edgerton C, McGillicuddy J, DuBay D, **Nadig SN.** "Utilization of the iliac artery as inflow in the morbidly obese during orthotopic liver transplantation." *Transplantation Proceedings*. In press

Books

1. **Satish N. Nadig MD, DPhil.** Immunoregulation of Transplant Arteriosclerosis. Balliol College, University of Oxford. Doctor of Philosophy. Date Defended 10/08.
2. Technological Advances in Organ Transplantation. Editors: **Satish N. Nadig** and Jason Wertheim. Springer Publishing. Anticipated Publication Date March 2017.

Book Chapters

1. **Satish N. Nadig MD** and Benjamin Schneider, MD. "The Treatment of Gallbladder Disease in Morbid Obesity." The SAGES Manual III Edition Chapter 22. Springer Publishing.
2. **Satish N. Nadig MD** and Allen Hamdan, MD. "Atherosclerosis and Peripheral Vascular Disease: Sequelae of Obesity and Diabetes." Chapter 18 Obesity and Diabetes. Humana Press.
3. **Satish N. Nadig MD**, Gregor Warneke MD, and Kathryn J. Wood D.Phil. "Approaches to the Induction of Tolerance." Kidney Transplantation: Principles and Practice, 6th Edition Editors: Sir Peter J. Morris AC FRS FRCS and Stuart Knechtle MD FACS. Chapter 23. Saunders Elsevier.
4. Kathryn J Wood, Andrew Bushell, Manuela Carvalho-Gaspar, Gang Feng, Ross Francis, Nick Jones, Elaine Long, Shiqiao Luo, Ian Lyons, **Satish Nadig**, Birgit Sawitzki, Gregor Warnecke, Bin Wei and Joanna Więckiewicz. Chapter 16 "Regulatory T cells in Transplantation." Regulatory T cells and Clinical Application. Editor: Dr Shuiping Jiang. Springer, New York.

5. **Satish N. Nadig** and Charles M. Vollmer. Chapter 38. Post-Cholecystectomy Problems. Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas. 5th Edition. Editors Leslie Blumgart and William Jarnagin.
6. **Satish N. Nadig**, Mark Gromski and Alan Lisbon. Surgical Critical Care. Pocket Surgery. Editors Goldfarb, Gromsky, Hurst and Jones. Lippincott Williams Publisher.
7. David D. Lee, Christie W Gooden, **Satish N. Nadig**, Christopher J. Sonnenday, Chad Abbott, John C. Magee, Michael J. Englesbe, Jeffrey D. Punch, Milagros Samaniego, Robert M. Merion, and Randall S. Sung. Living Donor Kidney Transplantation at the University of Michigan. Clinical Transplants 2011.77-89.
8. **Satish N. Nadig** and Jeffrey D. Punch. Organ Transplantation. Current Diagnosis & Treatment – Surgery. 14th Edition. Chapter 45. Ed: Gerard Doherty. McGraw –hill Publisher.
9. Amit K Mathur and **Satish N. Nadig**. Clincial Transplant Immunology. Greenfield's Surgery: Scientific Principles & Practice. 6th Edition. *In Press.*
10. Vinayak Rohan, Emad Kishi, John Mcgillicuddy, and **Satish N. Nadig**. Perioperative Complicationsin Transplant Surgery. Principles and Practice of Hospital Medicine. 2nd Edition. *In press.*

Abstracts and Presentations

1. **Satish N. Nadig** and Kenneth D. Chavin. The Effect of Ischemia Reperfusion on Steatotic ivers. Oral Presentation. 2nd *Place Medical University of South Carolina's Student Research Day.*
2. Stephen F. Shafizadeh, Ryan N. Fiorini, Jeremy F. Kirtz, John R. McEvoy, Julia K. Haines, Prabhaker Baliga, Jeffery Rogers, Angello Lin, PR Rajagopalan, Graham M. Bundy, **Satish N. Nadig**, Kenneth D. Chavin. Uncoupling Protein-2 is Upregulated in Steatotic Livers: Is this the Cause of Primary Non-Function? Poster Presentation. 1st *Place 10th Annual South Carolina Research Competition on Molecular Approaches to Biological Problems*
3. Chavin KD, Shafizadeh SF, Haines JK, **Nadig SN**, Nichols L, Fiorini R, Mora NP, Self S, Schmidt M: Uncoupling Protein-2 Is Upregulated in Steatotic Human Livers: Is this the Cause of Primary Nonfunction. Transplant 2001, Chicago, IL.
4. Chavin KD, Shafizadeh SF, Fiorini R, Kirtz J, **Nadig SN**, Haines JK, Nichols L, Mora NP, Baillie GM, Rogers J, Lin A, Baliga PK: Marginal Fatty Livers May Be an Untapped Resource to Expand the Donor Pool. Transplant 2001, Chicago, IL.
5. **Satish Nadig**, Basker Periyasamy, Ryan Fiorini, David Rodwell, Stephen Shafizadeh, Carmen Polito, Dana Dunkelberger, Michael Schmidt, Sally Self, and Kenneth Chavin. Hepatocellular Ultrastructure after Ischemia/Reperfusion Injury in Human Orthotopic Liver Transplantation. Abstract #202. American Transplant Congress 2004, Boston, MA.
6. Gregor Warnecke, Andrew Bushell, **Satish N. Nadig** and Kathryn J. Wood: Alloantigen-reactive CD25⁺CD4⁺ regulatory T cells generated *in vivo* inhibit transplant arteriosclerosis. World Transplant Congress, 2006, Boston, MA.

7. **Satish N. Nadig** and Kathryn J. Wood. "The impact of human regulatory T cells on transplant Arteriosclerosis." The Transplantation Society. New Key Opinion Leader Conference 2007. Sydney, Australia.
8. Gregor Warnecke, Gang Feng, Andrew Bushell, **Satish N. Nadig** and Kathryn J. Wood: CD4⁺ T Cells Conditioned *in vitro* with IFN-gamma and allo-APC abrogate transplant arteriosclerosis caused by CD25⁻CD4⁺ effectors – role of restimulation with alloantigen. World Transplant Congress, 2006, Boston, MA.
9. Gregor Warnecke, Christina A. Bursill, Manuela Carvalho-Gaspar, **Satish N. Nadig**, David R. Greaves, Keith M. Channon and Kathryn J. Wood: Broad spectrum CC- chemokine inhibition attenuates transplant arteriosclerosis caused by a minor antigen mismatch – importance of IFN-gamma. World Transplant Congress 2006, Boston, MA.
10. J. Więckiewicz, **S.N. Nadig**, D.C. Wu, G. Warnecke, W. Zhang, S. Luo, D. Taggart, and K.J. Wood. Human Regulatory T Cell Therapy in the Prevention of Transplant Arteriosclerosis. World Transplant Congress 2008. Sydney, Australia. Oral Presentation.
11. *Ex vivo* Generated Treg Ameliorate Transplant Arteriosclerosis by Inhibiting Effector Cell Priming and Graft Infiltration. Ross S. Francis, Gregor Warnecke, **Satish N. Nadig**, Gang Feng, Kathryn J. Wood, Andrew R. Bushell. World Transplant Congress 2008. Sydney, Australia. Oral Presentation.
12. Alexandru Schiopu, **Satish N. Nadig**, and Kathryn J. Wood. Plasma Lipids Infiltrate Arterial Allografts and Accelerate the Development of Transplant Arteriosclerosis. World Transplant Congress 2008. Sydney, Australia. Oral Presentation
13. **Satish N. Nadig**, Joanna Więckiewicz, Douglas C. Wu, Gregor Warnecke, Wei Zhang, Shiqao Luo, David Taggart, and Kathryn J. Wood. *Ex Vivo* Expanded Human Treg Inhibit the Development of Transplant Arteriosclerosis in a Humanized *In Vivo* Model. "Philip K. Caves Award Candidate Presentations." International Society for Heart and Lung Transplantation 2008. Boston, MA.
14. Joanna Więckiewicz, **Satish Nadig**, Alex Schiopu, Douglas C. Wu, Gregor Warnecke, Wei Zhang, Shiqao Luo, David P. Taggart, and Kathryn J. Wood. *Ex Vivo* Expanded Human Treg Inhibit the Development of Transplant Arteriosclerosis in a Humanized *In Vivo* Model. Best Oral Presentation Award. ESOT Basic Science Symposium 2009. Brussels, Belgium.
15. **Nadig SN**, Alluri PG, Lee DD, Pelletier, SJ. Temporary Porto-Caval Shunting in Orthotopic Liver Transplantation: Is this technique the answer to bleeding and exposure? AHPBA Annual Conference 2012. Miami, FL.
16. **Nadig SN**, Pelletier SJ, Lee DD, Englesbe MJ, Sung RS, Magee JC, Fontana RJ, Punch JD. A prospective, Randomized Trial of Complete Steroid Avoidance in Liver Transplantation: Follow-up of over 7 years. 24th International Congress of the Transplantation Society 2012. Berlin, Germany. July 2012.
17. **Nadig SN**, Arcerito M, Lee DD, Punch JD, Pelletier SJ. Quantifying Hepatitis C

Viral (HCV) Load in HCV-Positive Liver Transplant Recipients: Influence of Steroid Therapy. The ILTS 18th Annual International Congress. San Francisco, CA. May 2012.

18. **Satish N. Nadig**, Joanna Hester, Alexandru Schiopu, and Kathryn Wood. Low dose rapamycin treatment increases the ability of ex vivo expanded human regulatory t cells to inhibit transplant arteriosclerosis in vivo. American Transplant Congress June 2012. Boston, MA.
19. Keith A. Thatch*, **Satish N. Nadig***, Eric Davies, David D. Lee, Shawn J. Pelletier, and Ronald B. Hirschl. Hepatic Explantation, ex vivo reconstruction and re-implantation for severe traumatic retrohepatic IVC and hepatic vein injuries. ACS Michigan Chapter. May 2012. Traverse City, MI.
20. Amit K. Mathur, **Satish N. Nadig**, Theodore H. Welling. The Effect of Endo-biliary Stenting on Post-operative Morbidity following Orthotopic Liver Transplantation. AHPBA 2013. Oral Presentation. Miami, FL.
21. Jessica Mellinger, **Satish N. Nadig**, and Robert J. Fontana. Epstein-Barr Virus (EBV) Related Acute Liver Failure: A Case Series from the US Acute Liver Failure Study Group. AASLD. 2012
22. Ann-Marie Broome, Natalie Levey, Suraj Dixit, Carl Atkinson, **Satish N. Nadig**. Towards Targeted Drug Delivery in Transplantation: *use of immunosuppressant nanoparticle therapy*. AST-CEOT. 2014
23. Ann-Marie Broome, Natalie Levey, Suraj Dixit, Carl Atkinson, **Satish N. Nadig**. Towards Targeted Drug Delivery in Transplantation: *use of immunosuppressant nanoparticle therapy*. TechConnect World Innovation Conference. Washington DC. July 2014.
24. C. Jordan, D. Taber, N. Pilch, J. Fleming, M. Oliver, J. Conelly, **S. Nadig**, A. Lin, J.W. Mcgillicuddy, I. Shatat, K. Twombly, K.D. Chavin, P. Baliga. Risk Factors for Development of Opportunistic Infections in Pediatric Renal Transplant Patients. WTC. San Francisco. July 2014.
25. M. Oliver, D. Taber, N. Pilch, J. Fleming, C. Jordan, J. Conelly, **S. Nadig**, J.W. Mcgillicuddy, K. Chavin, P. Baliga, K. Twombly. Evaluation of Racial Disparities in Pediatric Kidney Transplant. WTC. San Francisco. July 2014.
26. A. Finn, J. Sebaaly, N. Pilch, J. Fleming, A. Lin, **S. Nadig**, P. Baliga, K. Chavin, D. Taber. Impact of Pre-Transplant Opiate use on Outcomes in Liver Transplant Recipients. WTC. San Francisco. July 2014.
27. A. Finn, J. Sebaaly, N. Pilch, J. Fleming, A. Lin, **S. Nadig**, P. Baliga, K. Chavin, D. Taber. Resource Utilization of Patients on Opiates prior to Liver Transplant: The Squeaky Wheel Phenomenon? WTC. San Francisco. July 2014.
28. C. Staino, N. Pilch, D. Taber, S. Patel, K. Trobaugh, J. Fleming, H. Meadows, **S. Nadig**, T. Srinivas, K. Chavin, P. Baliga. Pharmacist Chart Reviews Cannot Replace Direct Care in the Management of Renal Transplant Recipients. WTC. San Francisco. July 2014.

29. Dennis W, Broome A-M, Dixit S, Atkinson C, **Nadig SN**. Targeted Nanotherapy Dampens MHC Expression in Human Endothelial Cells. P.V. Halushka Research Day. Nov 2014.
30. Naik A, Taber D, **Nadig SN**, Mcgillicuddy J, Bratton, C, Baliga P, Chavin K. Analysis of the Association Between Intraoperative flow rates and Post-Operative Vascular Complications. P.V. Halushka Research Day, Nov 2014.
31. Taraskiewicz D, Taber D, **Nadig SN**, Mcgillicuddy J, Chavin K, Baliga P, Bratton C. Choice of Induction Immunosuppression Influences Net Benefit of Transplant in Pancreas Subcategories. P.V. Halushka Research Day. Nov 2014
32. Broome AM, Levey N, Dixit S, Atkinson C, **Nadig S**. Towards Targeted Drug Delivery in Transplantation: use of immunosuppressant nanoparticle therapy. *ASTS Abstract Winter Meeting Miami. Jan 2015*.
33. Broome AM, Levey N, Dixit S, Atkinson C, **Nadig S**. Targeted Immunosuppressive Nanotherapy Dampens Antigen Presentation and the Production of Inflammatory Biomarkers by Human Endothelial Cells. *ASTS Abstract Winter Meeting Miami. Jan 2015*.
34. **Nadig S**, Dixit S, Zhu P, Atkinson C, Broome AM. Focused Nanotherapeutics Result in Biologic Uptake in a Relevant Model for Heart & Lung Transplantation. *ASTS Abstract Winter Meeting Miami. Jan 2015*.
35. Nadig S, Zhu P, Dixit S, Broome AM, **Atkinson C**. Targeted Ex-vivo Nanotherapy Provides Protection Against Alloimmune Destruction in Tracheal Transplantation. *ASTS Abstract Winter Meeting Miami. Jan 2015*.
36. Zhu P, Stephenson S, Finnegan R, **Nadig S**, Atkinson C. Stabilization of Gap and Tight Junctions with ACT1 Reduces Post Transplantation Ischemia Reperfusion Injury. *ASTS Abstract Winter Meeting Miami. Jan 2015*.
37. **Nadig SN**, Eskilsen S, Broome AM, Dixit S, and Atkinson, C. Targeted Rapamycin Nanotherapy Dampens Memory T Cell Function. *American Transplant Congress. Philadelphia, PA. May 2015*.
38. Zhu P, Eskilsen S, Broome AM, Atkinson C, **Nadig SN**. Bioengineered Immunotherapeutic Nanoparticles Prevent Transplant Vasculopathy In Vivo. *ASTS Winter Meeting. Miami, FL. Jan 2016*.
39. Ryan Finnegan, Peng Zhu, Sarah Stephenson, Kunal Patel, **Satish Nadig** and Carl Atkinson. Cold Storage Stabilization of Gap Junctions Reduces Post Transplant Ischemia Reperfusion Injury. ATC. Boston, MA. Jun 2016.
40. Grace Bazzle, Suraj Dixit, Kunal Patel, Ann-Marie Broome, **Satish Nadig** and Carl Atkinson. Rapamycin Encapsulated Nanoparticles as Pre-treatment in Lung Transplantation. ATC. Boston, MA. Jun 2016.
41. D. Taber, V. Phan, A. Wilton, N. Pilch, H. Meadows, J. Fleming, C. Mardis, A. Mardis, C. Bratton, K. Chavin, J. McGillicuddy, **S. Nadig**, P. Baliga. Tacrolimus Dosing, Trough

Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients. ATC. Boston, MA. Jun 2016.

42. Rohan, V, Taber DJ, Tarakiewicz D, **Nadig S**, McGillicuddy J, Chavin K, Baliga P, Bratton C. Do induction therapy, patient-level and post-operative factors impact outcomes in moderate to high immunologic risk simultaneous kidney-pancreas transplantation in the era of stringent HLA cross-matching? Am J Transplant 2015;15(S3):1792. ATC 2015 [poster]
43. Bratton C, Rohan V, **Nadig S**, McGillicuddy J, Chavin K, Baliga P, Taber DJ. Immunosuppression and reoperation after simultaneous kidney pancreas transplantation conveys greatest risk of rejection. Am J Transplant 2015;15(S3):1665. ATC 2015 [poster]
44. Fleming J, Taber DJ, Pilch NA, Meadows H, Mardis C, McGillicuddy JW, **Nadig S**, Chavin K, Baliga P, Bratton C. mTOR based CNI minimization versus withdrawal in African American kidney transplant recipients. Am J Transplant 2015;15(S3):476. ATC 2015 [poster]
45. C. Staino, N. Pilch, O. Moussa, K. Boyle, J. Casale, K. Covert, J. Fleming, D. Taber, H. Meadows, C. Mardis, K. Chavin, **S. Nadig**, J. McGillicuddy, C. Bratton, T. Srinivas, P. Baliga. Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients. ATC 2015[poster]
46. Effective Systems of Care Improve Outcomes in Liver Transplantation, Regardless of Patient-Level Risk Factors, Taber D, Chavin KD, Bratton CF, McGillicuddy J, **Nadig S**, Baliga P, The Liver Meeting 2015
47. Taber D, Phan V, Wilton A, Pilch N, Meadows H, Fleming J, Mardis C, Mardis A, Bratton C, Chavin K, McGillicuddy J, **Nadig S**, Baliga P. Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients. Am J Transplant. 2016; 16 (suppl 3)
48. Bazzle G, Dixit S, Patel K, Broome A-M, **Nadig S**, Atkinson C. Rapamycin Encapsulated Nanoparticles as Pre-Treatment in Lung Transplantation. Am J Transplant. 2016; 16 (suppl 3). ATC 2016 Boston.
49. K Patel, Q Cheng, L Rucker, G Bazzle, **S Nadig**, C Atkinson . N-acetylcystein potentiates the protective effects of alpha 1 antitrypsin in a mouse model of orthotopic lung transplantation. ISHLT. April 2017. San Diego.
50. K Patel, Q Cheng, R Finnegan, Z Ballish, L Rucker, **S Nadig**, C Atkinson. Augmentation of UW Solution with a gap and tight junction stabilizing peptide, α CT1, ameliorates ischemia reperfusion injury, facilitates prolonged graft storage, and protects against allograft vasculopathy. ISHLT. April 2017. San Diego.
51. Q Cheng, K Patel, P Zhu, L Rucker, P Allen, C Vasu, **S Nadig**, C Atkinson. Donor Organ Pre treatment with a gap and tight junction stabilizing peptide prevent IRI in a mouse lung transplant model. ISHLT. April 2017. San Diego.
52. Danh T. Tran, Catherine Dong, Ali Alawieh, Gyda Beeson, Carl Atkinson, **Satish N.**

Nadig. Static Cold Storage Induces Metabolic Alterations and Autophagy in Models of Cardiac Transplantation. Abstract #1150. ISHLT 37th Annual Meeting and Scientific Sessions 2017, San Diego, CA.

53. Danh T. Tran, Carl Atkinson, Ali Alawieh, Gyda Beeson, **Satish N. Nadig.** Rapamycin Reverses Metabolic Alterations Induced by Static Cold Preservation in Models of Transplantation. Abstract #119. ASTS 17th Annual State of the Art Winter Symposium 2017, Miami, FL.
54. Danh T. Tran, Catherine Dong, Ali Alawieh, Gyda Beeson, Carl Atkinson, **Satish N. Nadig.** Rapamycin Reverses Metabolic Alterations Induced by Static Cold Preservation in Models of Cardiac Transplantation. Abstract #139. MUSC Perry V. Haluska Research Day 2016, Charleston, SC.
55. Danh T. Tran, Catherine Dong, Carl Atkinson, **Satish N. Nadig.** Hypothermic Preservation Induces Mitochondrial Dysfunction and Metabolic Alteration in Models of Cardiac Transplantation. MUSC MSTP Research Day 2016, Charleston, SC.